Join
Live feed
·
PRReleasevia Quantisnow
Arvinas Inc. logo
Novartis AG logo

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ARVN· Arvinas Inc.NVS· Novartis AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARVN (Arvinas Inc.), NVS (Novartis AG) and more on Quantisnow.